Table 3 16 IHC markers and OS in the biomarker population.

From: Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer

  

OS (months)

P value

Pinteraction

Sunitinib

Sorafenib

Sunitinib

Sorafenib

HIF-1α

High

29.2

32.5

0.849 (1.073, 0.521–2.209)

0.921 (0.965. 0.473–1.968)

0.737

Low

36.5

38.5

HIF-2α

High

37

27.2

0.047 (0.474, 0.227–0.989)

0.310 (1.434, 0.715–2.877)

0.011

Low

20

40

CAIX

High

49

31.5

0.038 (0.461, 0.221–0.958)

0.260 (1.536, 0.728–3.244)

0.027

Low

21

31

VEGF

High

36.5

55

0.248 (0.652, 0.315–1.348)

0.024 (0.368, 0.154–0.879)

0.215

Low

32.1

25.8

VEGFR1

High

36.5

49

0.282 (0.672, 0.325–1.386)

0.103 (0.531, 0.249–1.136)

0.243

Low

29.6

29.1

VEGFR2

High

36.5

42

0.897 (0.950, 0.435,2.073)

0.515 (1.308, 0.582–2.940)

0.138

Low

24.8

31.5

VEGFR3

High

29.4

28.15

0.989 (1.005, 0.478–2.114)

0.765 (1.119, 0.535–2.341)

0.127

Low

33.25

37

PDGFB

High

36.5

37

0.373 (0.829, 0.352–1.912)

0.490 (1.343, 0.581–3.105)

0.121

Low

27.6

35

PDGFRB

High

29.7

49

0.457 (1.314, 0.640–2.696)

0.333 (0.700, 0.340–1.441)

0.130

Low

32.1

31.1

CD31

High

40.1

36.5

0.093 (0.529, 0.252–1.112)

0.921 (0.965, 0.473–1.968)

0.037

Low

24.65

33

CD44

High

24.8

36

0.033 (2.380, 1.071–5.289)

0.476 (1.302, 0.630–2.691)

0.562

Low

52

49

bcl-xL

High

21

36.5

0.011 (2.626, 1.244–5.543)

0.477 (0.772, 0.377–1.577)

0.465

Low

49

36

KIT

High

49

19.15

0.7140 (0.835, 0.324–1.334)

0.508 (1.280, 0.616–2.660)

0.622

Low

28.4

37

p21

High

29.2

31

0.185 (1.690, 0.778–3.671)

0.276 (1.494, 0.726–3.075)

0.600

Low

40.1

46

RET

High

28.05

25.2

0.236 (1.610, 0.732–3.540)

0.039 (2.377, 1.044–5.411)

0.452

Low

32.1

49

FLT-3

High

36.5

42

0.867 (0.939, 0.447–1.970)

0.600 (0.828, 0.410–1.676)

0.564

Low

29.4

30.6

  1. Survival data are median, p values and HRs for sunitinib- and sorafenib-treated groups are both come from multivariable analysis, they compare higher biomarker group to lower biomarker group; pinteraction values are come from multivariate analysis (Cox model analysis) to assess the potential differential effects of immunostainings between the two treatment groups.
Back to article page